Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 328
- Registration Number
- NCT00654875
- Locations
- 🇪🇸
Investigative Site, Valencia, Spain
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 774
- Registration Number
- NCT00631917
- Locations
- 🇪🇸
Investigative Site, Investigative Site, Spain
Combined Renin Inhibition/Beta-blockade
- Conditions
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00627861
- Locations
- 🇺🇸
The Rogosin Institute, New York, New York, United States
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)
- Conditions
- Interventions
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8606
- Registration Number
- NCT00549757
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Estado Miranda, Venezuela
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 178
- Registration Number
- NCT00542269
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1613
- Registration Number
- NCT00529451
- Locations
- 🇹🇭
Novartis Investigative Sites, Thailand, Thailand
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00518765
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 46
- Registration Number
- NCT00498433
- Locations
- 🇩🇪
Novartis Investigative Site, Hannover, Germany
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2011-02-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 26
- Registration Number
- NCT00464776
- Locations
- 🇩🇰
Novartis, Gentofte, Denmark
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
- Conditions
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00464880
- Locations
- 🇩🇰
Novartis, Gentofte, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.